{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T14:23:46Z","timestamp":1709043826505},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.gastrohep.2015.02.014","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T03:45:17Z","timestamp":1429587917000},"page":"501-510","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Manejo de los nuevos anticoagulantes orales (NACO) en hemorragia digestiva y procedimientos endosc\u00f3picos"],"prefix":"10.1016","volume":"38","author":[{"given":"F\u00e1tima","family":"del Molino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteve","family":"Saperas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2015.02.014_bib0325","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0330","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0335","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0340","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0345","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0350","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0355","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0360","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0365","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0370","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrilation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0375","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0380","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0385","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0390","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodymanics and tolerability of dabigatran etexilate, a new oral direct inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0395","first-page":"27","article-title":"Pharmacodymanic and farmacokinetic basics of rivaroxaban. Fundam","volume":"26","author":"Kreutz","year":"2012","journal-title":"Clin Pharmacol."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmakinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0405","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallelgroup, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0410","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjmed.2011.10.017","article-title":"Interpretation of point-of-care INR results in patients treated with dabigatran","volume":"125","author":"Van Ryn","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0415","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0420","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0425","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/clpt.2013.99","article-title":"Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: Systematic review and meta-analysis","volume":"94","author":"Lopes","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0430","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/europace\/eut001","article-title":"Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies","volume":"15","author":"Roskell","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0435","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0440","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0445","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0450","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1160\/TH14-02-0118","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis","volume":"111","author":"Skj\u00f8th F1","year":"2014","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0455","doi-asserted-by":"crossref","first-page":"e100478","DOI":"10.1371\/journal.pone.0100478","article-title":"Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons","volume":"9","author":"Verdecchia","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0460","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation. A prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0465","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0002-9343(88)90105-2","article-title":"Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy","volume":"84","author":"Wilcox","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0470","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/ajg.2009.164","article-title":"Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice","volume":"104","author":"Lanas","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0475","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.gastrohep.2013.12.008","article-title":"Gastrointestinal lesions and characteristics of acute gastrointestinal bleeding in acenocoumarol-treated patients]","volume":"37","author":"Nantes","year":"2014","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0480","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0485","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.acvd.2013.04.009","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) March 2013","volume":"106","author":"Pernod","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0490","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH13-02-0150","article-title":"Gastrointestinal bleeding with the new oral anticoagulants- defining the issues and the management strategies","volume":"110","author":"Desai","year":"2013","journal-title":"Thromb Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2015.02.014_bib0495","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1002\/ajh.23165","article-title":"Reversal of antithrombotic agents","volume":"87","author":"Bauer","year":"2012","journal-title":"Am J Hematol."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0500","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.beha.2013.07.001","article-title":"Bleeding and antidotes in new oral anticoagulants","volume":"26","author":"Majeed","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0505","first-page":"229","article-title":"On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage","volume":"22","author":"Holtster","year":"2013","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0510","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3949\/ccjm.80a.13025","article-title":"Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban","volume":"80","author":"Fawole","year":"2013","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.gastrohep.2015.02.014_sbref0515a","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH12-08-0573","article-title":"Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease","volume":"109","author":"Khadzhynov","year":"2013","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.gastrohep.2015.02.014_sbref0515b","doi-asserted-by":"crossref","first-page":"843","DOI":"10.7326\/0003-4819-139-10-200311180-00012","article-title":"Consensus recommendations for managing patients with non variceal upper gastrointestinal bleeding","volume":"139","author":"Barkun","year":"2003","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0520","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gut.35.4.464","article-title":"Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment","volume":"35","author":"Choudari","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0525","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1572-0241.2006.00969.x","article-title":"Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage","volume":"102","author":"Wolf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0530","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed A1","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0535","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0540","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1742-1241.2011.02827.x","article-title":"Risks related with withholding and resuming anticoagulation in patients with non-variceal upper gastrointestinal bleeding while on warfarin therapy","volume":"66","author":"Lee","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0545","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0550","article-title":"Thromboembolic events recurrent gastrointestinal bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding: A systematic review and meta-analysis","author":"Chai-Adisaksopha","year":"2014","journal-title":"56th ASH Annual meeting and exposition"},{"issue":"suppl 2","key":"10.1016\/j.gastrohep.2015.02.014_bib0555","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9.th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0560","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.gie.2009.09.040","article-title":"Management of antithrombotic agents for endoscopic procedures","volume":"70","author":"Anderson","year":"2009","journal-title":"Gastrointest Endosc."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0565","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0030-1256317","article-title":"Endoscopy and antiplatelet agents","volume":"43","author":"Bousti\u00e8re","year":"2011","journal-title":"Endoscopy"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0570","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMra1206531","article-title":"Management of antithrombotic therapy in patients undergoing invasive procedures","volume":"368","author":"Baron","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0575","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.gie.2013.04.179","article-title":"Novel oral anticoagulants in gastroenterology practice","volume":"78","author":"Desai","year":"2013","journal-title":"Gastrointest Endosc."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0580","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0585","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/j.1572-0241.2001.04046.x","article-title":"Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study","volume":"96","author":"Goldstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0590","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.amjmed.2003.10.035","article-title":"The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis","volume":"116","author":"Gerson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0595","doi-asserted-by":"crossref","unstructured":"Spyropoulos AC, Bauersachs RM, Omran H, Cohen M. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin. 2006; 22: 1109\u2013 1122. 6. Kaatz S, Paje D. Update in bridging anticoagulation. J Thromb Thrombolysis. 2011; 31: 259\u2013 64.","DOI":"10.1007\/s11239-011-0571-z"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0600","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/CIRCULATIONAHA.112.092833","article-title":"Periprocedural bridging management of anticoagulation","volume":"126","author":"Wysokinski","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0605","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archinternmed.2007.23","article-title":"Risk of thromboembolism with short-term interruption of warfarin therapy","volume":"168","author":"Garcia","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0610","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1161\/01.CIR.0000142859.77578.C9","article-title":"Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin","volume":"110","author":"Kovacs","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0615","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1538-7836.2011.04572.x","article-title":"Predictors of major bleeding in peri-procedural anticoagulation management","volume":"10","author":"Tafur","year":"2012","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0620","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.112.105221","article-title":"Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates","volume":"126","author":"Siegal","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0625","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH14-04-0305","article-title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients with an elective surgery or procedure, Substudy of the RE-LY trial","volume":"113","author":"Douketis","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0630","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis","volume":"104","author":"Si\u00e9","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0635","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2007-966959","article-title":"Risk factors for severe delayed postpolypectomy bleeding","volume":"40","author":"Sawhney","year":"2008","journal-title":"Endoscopy"},{"key":"10.1016\/j.gastrohep.2015.02.014_bib0640","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cgh.2013.09.049","article-title":"Risk factors for intraprocedural and clinically significant delayed bleeding after wide-field endoscopic mucosal resection of large colonic lesions","volume":"12","author":"Burgess","year":"2014","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051500093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051500093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T21:19:55Z","timestamp":1566595195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057051500093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S021057051500093X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2015.02.014","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manejo de los nuevos anticoagulantes orales (NACO) en hemorragia digestiva y procedimientos endosc\u00f3picos","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2015.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}